The accuracy of automated oscillometric devices has been questioned. In addition the acceptability of these devices for research under the field conditions is unclear.
A utomated oscillometric devices are increasingly used for blood pressure (BP) measurement in research and clinical settings, because they are easy and safe to use and also free of observer bias. Unlike the standard mercury sphygmomanometer that determines BP by detecting Korotkoff sounds with a stethoscope over the brachial artery while deflating the cuff, an oscillometric device determines BP by detecting a sequence of oscillations in cuff pressure. 1, 2 Because of the difference in the mechanisms for BP measurement, concern has been raised that systolic and diastolic BP may not represent the same physiologic entity when measured with these two modalities. 2 Previous validation studies of oscillometric devices have generated inconsistent results with respect to the magnitude and direction of the discrepancies, possibly because of the differences in study design, characteristics of study participants, and instruments used for the valida-tion. [3] [4] [5] [6] [7] [8] [9] [10] [11] Recent studies suggested that the differences in performance between the devices could also be related to arterial stiffness or conditions associated with arterial stiffness. 12, 13 To date most validation studies have been limited to patients in clinical settings such as hospitals and operating rooms, the results of which may not be applicable to the general population. Because of the advantages of oscillometric devices in large-scale epidemiologic studies, population-based studies are needed to quantify the differences, to elucidate the determinants of the consistency between mercury and each automated device, and to determine the acceptability of the devices under field conditions.
The objectives of this study were to compare the Dinamap PRO-100 with a standard mercury sphygmomanometer for the measurement of BP and to assess the factors influencing the magnitude and direction of the discrepancies of the two devices in a population-based cohort of participants aged 48 to 86 years.
Methods

Study Population
The study participants of this study were from the MultiEthnic Study of Atherosclerosis (MESA). MESA is a prospective multicenter study designed to investigate the occurrence and progression of subclinical cardiovascular disease in a population-based sample of non-Hispanic white (white), non-Hispanic African American (African American), Hispanic, and Chinese Americans without a history of cardiovascular disease. Between July 2000 and August 2002, a total of 6814 adults aged 45 to 84 years were recruited from six field centers: Forsyth County, NC; St. Paul, MN; Chicago, IL; New York, NY; Baltimore, MD; and Los Angeles County, CA. A detailed description of the study sampling, design, and objectives was previously published. 14 To validate the Dinamap PRO-100 device (Critikon, Milwaukee, WI) against a standard mercury sphygmomanometer (Baum Mobile Mercury Sphygmomanometer, 0661-0250, Copiague, NY), between April and August 2004, a total of 305 participants (approximately 50 participants from each MESA field center) were randomly selected using a stratified sampling strategy by two levels of pulse pressure (Ͻ60 mm Hg and Ն60 mm Hg), based on a previous MESA examination 2 years earlier. Persons requiring thigh cuffs or those with a diagnosis of atrial fibrillation were not eligible for this study. All participants gave written informed consent. Institutional review board approval was obtained at each of the six participating field centers.
Measurement of BP
A standardized protocol was used to train each technician and to obtain BP data. Participants were seated in a chair with back support, with both feet resting comfortably on the floor and both forearms supported on a level surface. After a 5-min rest, the study participants had their BP measured three times by one device and then, after another 5-min rest, by the other device. Dinamap measurements were repeated at a predetermined interval of 1 min. Sphygmomanometer measurements were repeated after 30 sec. The order of device use was assigned at random. If the Dinamap measurements were made first, a different technician made the sphygmomanometer measurements to avoid observer bias. All machines were calibrated before the study. The measurements were taken in a quiet room with an ambient temperature between 70°and 76°F. Cuff size was selected according to arm circumference. The appropriate cuff was used for both devices in each sequence of measurements. The cuff was placed on the right arm. A form was used to record BP readings, order of device, arm used, cuff size, technician identity, and room temperature. A total of 24 technicians were involved in the BP measurements.
Medical Conditions and Other Data
All data were collected in a standardized manner at all study sites by trained personnel. A questionnaire was used to collect data on demographic (ie, age, gender, and race/ ethnicity) and lifestyle (ie, smoking, alcohol use, and physical activities) characteristics as well as a history of medical conditions. Participants were asked to bring all currently used prescription and nonprescription medications and supplements to the clinic, where they were recorded.
Pulse pressure (systolic pressure minus diastolic pressure) was determined by the Dinamap device based on the estimates from the current study and classified as Ͻ60 mm Hg or Ն60 mm Hg. Height, weight, and waist circumference were measured from the participants in light examination clothing and without shoes. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters, squared. Obesity was classified as BMI Ն30 kg/ m 2 . Hypertension status was classified according to the Seventh Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7). 15 Diabetes was defined according to a previous physician diagnosis, use of diabetes medication, or fasting glucose of Ն126 mg/dL. Presence and volume of coronary artery calcification (CAC) were measured by computed tomography (CT). The CT scans were read centrally at the Harbor-University of California Los Angeles (Harbor-UCLA) Research and Education Institute. Using duplicate scans, interscan variability was calculated on a quality control sample at each of the scanning sites. Inter-and intro-reader variability were assessed on a 5% sample on a monthly basis.
Statistical Analyses
For each participant and device, the average of the second and third readings was used. The first reading was ex-cluded to reduce the impact of reactivity (higher first reading) and to increase the comparability of the BP measures by the two devices, because BP of each participant were not measured simultaneously by the two devices. The paired t test was used to examine differences between the BP obtained by the two devices (Dinamap minus mercury sphygmomanometer measurements) of these per-person averages.
We also compared the percentages of participants who were classified as having high systolic BP (Ն140 mm Hg), high diastolic BP (Ն90 mm Hg), or hypertension (Ն140/90 mm Hg) using the two devices, based on the BP measurements from the two devices only (and not medication use). The consistency and correlation of the measurements by the two devices were assessed by the kappa statistic and the Pearson correlation coefficient. Bland-Altman plots were used to determine whether the magnitude of the difference in paired measurements was associated with the level of BP. 16 Multiple linear regression analysis was conducted to identify factors influencing the magnitude of the difference. Factors considered were age group (48 to 64 years, 65 to 74 years, or Ն75 years of age); gender; obesity (yes or no); pulse pressure level (Ͻ60 or Ն60 mm Hg); coronary artery calcification score (0 or Ͼ0); hypertension (yes or no); and diabetes (yes or no). Backward selection technique was used to determine the best-fit model. Significance tests were conducted at the 0.05 level.
Results
Approximately one half (50.5%) of the participants had their BP measured first by the Dinamap PRO-100 and then by the mercury sphygmomanometer. Based on the earlier Dinamap measurement, 124 (40.7%) participants had a pulse pressure of 60 mm Hg or higher. This Dinamapmeasured pulse pressure was significantly correlated with the mercury sphygmomanometer-measured pulse pressure (r ϭ 0.81, P Ͻ .001). The mean age of the study participants was 62.6 years (SD ϭ 10.0 years). Hypertension, which was defined based on BP measures and treatment for hypertension, was present in 46.6% of the participants, diabetes in 15.1%, and obesity in 32.1% (Table 1) . Compared with the participants with pulse pressure Ͻ60 mm Hg, participants with pulse pressure Ն60 mm Hg were more likely to be African American or Hispanic, older, and obese, and to have diabetes or hypertension. A slightly larger percentage of participants with coronary artery calcification was observed in subjects with pulse pressure Ն60 mm Hg compared with subjects with pulse pressure Ͻ60 mm Hg (58.1% v 53.0%). or who had optimal or normal BP (Table 2 ). However the Dinamap-measured systolic BP tended to be higher than the mercury sphygmomanometer-measured systolic pressure in the participants who were 75 to 86 years of age, who were obese, who had a pulse pressure Ն60 mm Hg, or who had stages I to III hypertension. For diastolic BP, the Dinamap measurement was lower than the mercury sphygmomanometer measurements in all subgroups of age, gender, pulse pressure level, diabetes, or BP level. However the magnitude of the differences was significantly less among persons who were 75 to 86 years of age, who had a pulse pressure Ն60 mm Hg, who had stages I to III hypertension, or who had a CAC score Ͼ0. Table 3 presents the percentages of the absolute differences between the two device measurements that were within 5, 10, and 15 mm Hg. Overall, for systolic BP, 45% of systolic pressure readings were within 5 mm Hg, 74% within 10 mm Hg and 91% within 15 mm Hg of the mercury sphygmomanometer. For diastolic BP, 58% of systolic readings were within 5 mm Hg, 85% within 10 mm Hg, and 95% within 15 mm Hg of the mercury sphygmomanometer. Agreement between Dinamap and mercury measurements was similar in diastolic pressure between the two pulse pressure groups, but was slightly better in systolic pressure for participants with pulse pressure Ͻ60 mm Hg than for those with pulse pressure Ն60 mm Hg.
The BP values obtained using the two devices were well correlated (r ϭ 0.81 for diastolic BP and r ϭ 0.89 for systolic BP, P values Ͻ .001). Figures 1 and 2 present the Bland-Altman plots of differences in each systolic and diastolic BP pairs against the corresponding average BP Grade level for the blood pressure differences from this study was obtained by comparing the percentages of absolute differences within Յ5, Յ10, and Յ15 mm Hg with the British Hypertension Society criteria.
level by gender and pulse pressure level. No association was seen between the magnitude of the differences and level of BP at each subgroup of gender and pulse pressure level. Table 4 indicates that the classifications of hypertension (Ն140/90 mm Hg) by the Dinamap PRO-100 device and the mercury sphygmomanometer were consistent (kappa ϭ 0.71, P Ͻ .001). Although systolic BP measured by the 
FIG. 2.
Bland-Altman plot of differences against average systolic blood pressure, measured by Dinamap device versus standard mercury sphygmomanometer, according to gender and pulse pressure. S-AVG ϭ average of the Dinamap and mercury sphygmomanometer measured systolic blood pressures; S-DIFF ϭ Difference of the Dinamap and mercury sphygmomanometer measured systolic blood pressures.
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Dinamap device was slightly lower on average than that obtained by the mercury sphygmomanometer, a slightly higher proportion of participants with high systolic BP (Ն140 mm Hg) was identified by the Dinamap than by mercury sphygmomanometer (26.9% v 23.0%, P ϭ .26). Approximately 20% (n ϭ 60) of participants were classified as having high systolic BP by both devices. Consistent with the measure of the mean difference, Dinamap identified a slightly lower proportion of the participants with high diastolic BP (Ն90 mm Hg) as compared with the mercury sphygmomanometer (2.6% v 4.9%, P ϭ .14). Approximately 2% (n ϭ 5) of the participants were classified as having high diastolic BP by both devices. Overall, without considering the use of medication for hypertension, the prevalence of hypertension classified by the Dinamap-measured BP was slightly higher than that by the mercury sphygmomanometer-measured BP (26.9% v 24.3%), but the difference was not statistically significant (P ϭ .46). Multiple linear regression analyses showed that the most predictive factors for the discrepancy between the two devices were age (␤-coefficient ϭ 0.113, P ϭ .06), pulse pressure (␤-coefficient ϭ 0.145, P ϭ .01), and CAC score (␤-coefficient ϭ 0.134, P ϭ .02) for diastolic BP. For systolic BP, the single most predictive factor for the discrepancy between the two devices was pulse pressure (␤-coefficient ϭ 0.335, P Ͻ .001) (data not shown). Controlling for the measurement order of the two devices did not change the results.
Discussion
The results from this study indicate that, on average, the Dinamap PRO-100 device measurements tends to slightly underestimate BP-particularly diastolic BP-compared with the mercury sphygmomanometer in a populationbased cohort. Unlike previous reports, the magnitude of the average difference was found to be smaller for systolic BP than for diastolic BP, but the SD was smaller for diastolic than for systolic BP. [17] [18] [19] This study also indicates that the magnitude and direction of the discrepancy may vary with age, pulse pressure, and BP level. Given the overestimation of systolic pressure in older persons or in those with high pulse pressure, the Dinamap measurement, compared with the mercury measurement, might result in a slightly higher estimate of the prevalence of hypertension in population-based cohort aged Ն48 years. However, a larger study would be necessary to take into account factors such as age that might differentially affect the estimate of hypertension prevalence using the two devices.
Most previous validation studies have reported that, on average, Dinamap devices underestimate diastolic BP but overestimate systolic BP compared with values obtained using a standard or random zero mercury sphygmomanometer. 5,6,8,11,12,19 -22 These studies were mostly conducted among patients in clinical settings such as hospitals and operation rooms. In this population-based study the underestimation of diastolic pressure by the Dinamap PRO-100 was also observed, but the overestimation of systolic BP was seen only in persons Ն75 years of age or in those with conditions such as hypertension, diabetes, or obesity. For individuals 48 to 74 years of age and for those without hypertension, diabetes, or obesity, the Dinamap PRO-100 tended to underestimate minimally the systolic BP compared with values obtained with the mercury sphygmomanometer. Similar results were previously reported by two previous validation studies on different Dinamap models. 23, 24 The conflicting results may be explained by differences in the Dinamap model, selection of the validation criterion (standard or random zero mercury sphygmomanometer), or characteristics of study participants, such as age and health status.
Our results conflict somewhat with a recent finding from van Popele et al that the Dinamap 8100 tended to overestimate both systolic and diastolic BP readings in participants with stiff arteries as defined by pulse wave velocity. 25 As in the van Popele study we found that, compared with the mercury measurements, the Dinamapmeasured systolic BP was slightly higher in persons with pulse pressure Ն60 mm Hg, which was seen in all three age groups independent of the hypertension, diabetes, and obesity (data not shown). Diastolic BP, however, was underestimated by the Dinamp PRO-100 regardless of pulse pressure level, although the magnitude of the average difference was smaller in persons with pulse pressure Ն60 mm Hg. We also found that the discrepancy in diastolic BP was significantly associated with coronary artery calcification, which is another factor associated with arterial stiffness. 26 -28 This association was independent of age, hypertension, or diabetes. We did not find this association in systolic BP but identified pulse pressure as the single most predictive predictor for the discrepancy in systolic BP. Further analysis showed that in this study the CAC score was not well correlated with pulse pressure (for all participants: r ϭ 0.04, P ϭ .45; for those with CAC score Ͼ0: r ϭ 0.01, P ϭ .84). Therefore the role of coronary artery calcification in the discrepancy of the two devices is unclear. In addition we found that the Dinamap tended to overestimate systolic BP for diabetic participants, which is consistent with previous studies. 12, 13, 23, 29 The mechanism by which arterial stiffness may contribute to the discrepancy between the two devices is unclear, especially because studies to date have generated inconsistent results. The implication of the results is that the estimated prevalence of hypertension may tend to be slightly higher when BP is assessed by the Dinamap device than by standard mercury sphygmomanometer in persons with stiffer arteries. To our knowledge the possible impact of arterial stiffness on BP measurement has not been documented or cautioned against in any of the Dinamap device manuals. Because Dinamap devices are increasingly used in clinical settings and research, health care providers and researchers should know of this variation and should interpret these measurements with caution.
Compared with the criteria established by the Association for the Advancement of Medical Instrumentation, 30 the Dinamap PRO-100 would not be an acceptable device for either diastolic BP (SD Ͼ6.25 mm Hg for a mean difference of 2.9 mm Hg) or for systolic BP (SD Ͼ6.93 mm Hg with a mean difference of 0.5 mm Hg). Compared with the British Hypertension Society criteria, which requires at least a grade B (Ն50% of measurement differences Ͻ5 mm Hg, 75% Ͻ10 mm Hg, and 90% Ͻ15 mm Hg) for both systolic and diastolic BP, 31 the Dinamap PRO-100 would receive grade B for diastolic BP and a grade C for systolic BP. However, it is important to note that the present study was not designed based on the Association for the Advancement of Medical Instrumentation or British Hypertension Society standard protocol, which require a specific percent distribution in terms of age, cuff size, and ranges of BP in selected study subjects. These design features were not feasible for MESA because it was conducted in middle-aged and older persons who were free of cardiovascular disease at baseline. In addition, the objective of the study was to assess the comparability of the Dinamap to the mercury device under field conditions.
Another limitation of our study was that both oscillometric and mercury sphygmomanometers are indirect methods for measuring BP, and there is a lack of a true gold standard such as an intra-arterial BP measure. It is known that the computational algorithm used by the Dinamap is derived and tested using intra-arterial BP measurements. However whether intra-arterial BP measurements are more of a true gold standard than indirect measurements is questionable. Using a standard sphygmomanometer as a criterion to assess the accuracy of the Dinamap PRO-100 is clinically relevant, as the development of BP measurements are based on a noninvasive and indirect approach.
